<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gene test interpretation: Congenital long QT syndrome genes (&lt;i&gt;KCNQ1&lt;/i&gt;, &lt;i&gt;KCNH2&lt;/i&gt;, &lt;i&gt;SCN5A&lt;/i&gt;)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gene test interpretation: Congenital long QT syndrome genes (<i>KCNQ1</i>, <i>KCNH2</i>, <i>SCN5A</i>)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gene test interpretation: Congenital long QT syndrome genes (<i>KCNQ1</i>, <i>KCNH2</i>, <i>SCN5A</i>)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael J Ackerman, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Samuel Asirvatham, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1367877781"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This monograph discusses an approach to the results of<em> </em>genetic testing for the three major genes associated with congenital long QT syndrome (LQTS).</p><p>It does not discuss every LQTS-susceptibility gene, and it is not intended to replace clinical judgment in the decision to test or in the care of the individual who was tested. These subjects are discussed separately in UpToDate [<a href="#rid1">1</a>]. (See <a class="local">'Resources'</a> below.)</p><p class="headingAnchor" id="H3842481902"><span class="h1">HOW TO READ THE REPORT</span></p><p class="headingAnchor" id="H3144601347"><span class="h2">Review and verify</span><span class="headingEndMark"> — </span>The table summarizes important considerations in reviewing a genetic test report  (<a class="graphic graphic_table graphicRef122437" href="/d/graphic/122437.html" rel="external">table 1</a>). </p><p>All testing should be performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory or other nationally certified laboratory. For any concerning or unexpected finding obtained by direct-to-consumer testing or for research (positive result or negative result in an individual with suspected LQTS), testing should be repeated in a CLIA-certified laboratory with input from a specialist (genetic cardiologist, pediatric/adult heart rhythm expert, or genetic counselor with heart disease expertise). </p><p>Specialist input is also prudent to ensure that the appropriate testing is done (genetic testing and clinical evaluations) and the appropriate follow-up and interventions are in place. (See <a class="local">'Implications for management'</a> below.)</p><p class="headingAnchor" id="H4229779607"><span class="h2">Patient and family history</span><span class="headingEndMark"> — </span>Information from genetic testing should be reviewed in the context of personal and family history. </p><p class="bulletIndent1"><span class="glyph">●</span>Negative results or a variant of uncertain significance (VUS) cannot be ignored in a person with a positive personal or family history (unless the familial variant has been excluded and the electrocardiogram [ECG] is normal) [<a href="#rid2">2</a>]. This is because the test may not have covered all relevant variants and genes. (See <a class="local">'Individuals with a VUS or a negative genetic test result'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A positive result may indicate an abnormal genetic finding that is important but does not explain the familial disorder. (See <a class="local">'Genes'</a> below.)</p><p></p><p class="headingAnchor" id="H2090959381"><span class="h1">OVERVIEW OF CONGENITAL LQTS</span></p><p class="headingAnchor" id="H1879741932"><span class="h2">Genes</span><span class="headingEndMark"> — </span>Three LQTS-susceptibility genes account for approximately 80 percent of congenital LQTS cases/families: </p><p class="bulletIndent1"><span class="glyph">●</span><em>KCNQ1 </em>(LQT1) – 35 to 45 percent</p><p class="bulletIndent1"><span class="glyph">●</span><em>KCNH2</em> (LQT2) – 25 to 35 percent</p><p class="bulletIndent1"><span class="glyph">●</span><em>SCN5A</em> (LQT3) – 5 to 10 percent</p><p></p><p><em>KCNQ1</em> and <em>KCNH2</em> encode pore-forming subunits of outward-rectifying potassium (K<sup>+</sup>) channels in cardiomyocytes. <em>SCN5A</em> encodes the alpha subunit of the cardiac sodium (Na<sup>+</sup>) channel. Their molecular roles have been well characterized [<a href="#rid3">3</a>]. </p><p>Variant classification is summarized in the table  (<a class="graphic graphic_table graphicRef122646" href="/d/graphic/122646.html" rel="external">table 2</a>). For pathogenic and likely pathogenic variants in LQTS genes, confidence is high that they produce gene products that interfere with channel formation and function and that can impair cardiomyocyte repolarization. (See <a class="local">'Clinical features'</a> below.)</p><p>However, variants in these genes are not exclusive to congenital LQTS; they can also cause other disorders. </p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Some <em>KCNQ1 </em>(LQT1) and <em>KCNH2</em> (LQT2)<em> </em>variants cause congenital LQTS; others cause congenital <strong>short</strong> QT syndrome (SQT2 and SQT1, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some <em>SCN5A </em>variants cause congenital LQT3; others cause Brugada syndrome (BrS1). </p><p></p><p>A patient's disorder may not be immediately obvious from genetic test results or clinical history. (See  <a class="medical medical_review" href="/d/html/974.html" rel="external">"Pathophysiology and etiology of sudden cardiac arrest"</a>.)</p><p>Other genes account for a smaller proportion of congenital LQTS  (<a class="graphic graphic_table graphicRef114927" href="/d/graphic/114927.html" rel="external">table 3</a>), and some cases remain genetically uncharacterized [<a href="#rid4">4</a>]. Transmission is typically autosomal dominant with incomplete penetrance  (<a class="graphic graphic_table graphicRef122429" href="/d/graphic/122429.html" rel="external">table 4</a>); rare autosomal recessive forms occur. </p><p>The overall prevalence of congenital LQTS is estimated at approximately 1 in 2000; there may be a greater proportion of individuals who have an LQTS-causative variant and a normal electrocardiogram (ECG). </p><p class="headingAnchor" id="H516817672"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Cardiac repolarization abnormalities can cause polymorphic ventricular tachycardia (VT), also called torsades de pointes, which can degenerate to ventricular fibrillation (VF). Symptoms can include arrhythmogenic syncope, syncope-induced generalized seizures, sudden cardiac arrest, or sudden cardiac death. Bradycardia and atrial arrhythmias can occur. </p><p>Due to incomplete penetrance  (<a class="graphic graphic_table graphicRef122429" href="/d/graphic/122429.html" rel="external">table 4</a>), 25 to 40 percent of individuals with an LQTS-causative variant (especially variant-positive family members) will have a normal ECG and a QTc value within the normal distribution for age and sex (this is also called genotype positive/phenotype negative LQTS or concealed LQTS). Due to variable expressivity, most individuals with a pathogenic or likely pathogenic LQTS variant may never become symptomatic. </p><p>Aside from symptoms attributable to LQTS, individuals with congenital LQTS-causative variants may come to medical attention for other reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>An ECG done for screening or an unrelated purpose that shows QT prolongation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic testing, often during evaluation of first-degree relatives of an affected individual, sometimes for other reasons.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An extracardiac manifestation of a rare congenital LQTS disorder (eg, sensorineural deafness).</p><p></p><p>The ECG is an important test in any person with suspected LQTS, and many individuals with congenital LQTS have ECG abnormalities (see <a class="local">'Evaluations'</a> below). However, some patients with congenital LQTS have a normal ECG, and the absence of ECG findings does not exclude the diagnosis. If an LQTS-causative variant is established for a family, the only way a relative can have the diagnosis excluded is to have both a normal ECG <strong>and</strong> a negative test for the familial LQTS variant.</p><p>Documenting a pathogenic or likely pathogenic variant in a congenital LQTS gene is sufficient for diagnosis but not required. Other criteria include repeated documentation of an otherwise unexplained QTc of &gt;500 milliseconds or a Schwartz LQTS score of &gt;3.5  (<a class="graphic graphic_table graphicRef113828" href="/d/graphic/113828.html" rel="external">table 5</a>). Provocative testing with treadmill or bicycle stress testing may be used in selected individuals. (See  <a class="medical medical_review" href="/d/html/1053.html" rel="external">"Congenital long QT syndrome: Diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H2440788946"><span class="h1">IMPLICATIONS FOR MANAGEMENT</span></p><p class="headingAnchor" id="H1017576651"><span class="h2">Individuals with a positive genetic test</span><span class="headingEndMark"> — </span>Individuals with a pathogenic or likely pathogenic variant in an LQTS gene meet criteria for congenital LQTS. They require a full clinical evaluation and interventions to reduce the risk of symptoms and sudden cardiac arrest or sudden cardiac death. (See  <a class="medical medical_review" href="/d/html/1053.html" rel="external">"Congenital long QT syndrome: Diagnosis"</a>.)</p><p>These evaluations and interventions are also necessary for individuals with negative genetic testing who meet other criteria for congenital LQTS (genotype negative/phenotype positive LQTS).</p><p class="headingAnchor" id="H4231318099"><span class="h3">Evaluations</span><span class="headingEndMark"> — </span>All individuals require review of a 12-lead electrocardiogram (ECG) and assessment of the rate-corrected QT interval (QTc) on more than one occasion by an experienced clinician. In most cases, especially if the initial ECG appears normal, more than one ECG should be serially reviewed.</p><p>Additional evaluations include:</p><p class="bulletIndent1"><span class="glyph">●</span>Careful symptom review and family history.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation for secondary causes of QT prolongation, including electrolyte abnormalities and medications  (<a class="graphic graphic_table graphicRef57431" href="/d/graphic/57431.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ambulatory ECG monitoring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treadmill ECG with review of QT response to exercise.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ECG review for first-degree relatives.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Review of genetic test results by a knowledgeable genetic cardiologist, pediatric/adult heart rhythm specialist, and/or cardiovascular genetic counselor.</p><p></p><p class="headingAnchor" id="H1173690838"><span class="h3">Interventions</span><span class="headingEndMark"> — </span>A number of approaches are available to reduce the risk of complications, ranging from relatively straightforward (avoidance of triggers for QT prolongation) to more invasive interventions. The table  (<a class="graphic graphic_table graphicRef129223" href="/d/graphic/129223.html" rel="external">table 7</a>) summarizes a general approach to deciding among these interventions, with variations depending on genotype, patient values, and input from a heart rhythm disease expert [<a href="#rid5">5-9</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoid arrhythmia triggers </strong>– Triggers of arrhythmia are summarized in the table  (<a class="graphic graphic_table graphicRef57431" href="/d/graphic/57431.html" rel="external">table 6</a>). Methods of reducing them include: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dehydration</strong> – Ensure adequate hydration, especially with exercise or gastrointestinal symptoms (nausea, anorexia, diarrhea).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypokalemia/hypomagnesemia</strong> – Avoid medications that lower potassium or magnesium; use supplements if needed (especially for individuals with LQT2 [disease variants in <em>KCNH2</em>]). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Catecholamines</strong> – Stay active and exercise recreationally. Participation in competitive sports should be guided by a genetic cardiologist or pediatric/adult heart rhythm specialist with experience in risk stratifying and treating patients with LQTS. Limit noise and stress as appropriate (individualized according to genotype and risk tolerance). </p><p></p><p class="bulletIndent2">Specific activity restrictions may vary by genotype. As an example, arrhythmias triggered by swimming/diving are more common in LQT1 (disease variants in <em>KCNQ1</em>), while arrythmias triggered by noise and other auditory startles are more likely in patients with LQT2 (disease variants <em>in KCNH2</em>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Medications</strong> – Drugs that prolong the QT interval (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.crediblemeds.org%2F&amp;token=F2fTJXWTbAdqtiUVhUGfEeHvm%2Bapw8j0DIpr7ZimhTcQDLZbSKKNNIJ4B%2FwprPZ%2F&amp;TOPIC_ID=128462" target="_blank">www.crediblemeds.org</a>) are generally avoided, especially if a suitable alternative is available [<a href="#rid10">10</a>]. The benefits of a medication may outweigh the risks in some cases (eg, attention deficit hyperactivity disorder [ADHD] or psychosis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta blockade</strong> – All individuals with a prolonged QTc are strongly urged to take a nonselective beta blocker (<a class="drug drug_general" data-topicid="9672" href="/d/drug information/9672.html" rel="external">nadolol</a> or <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>) [<a href="#rid11">11,12</a>]; beta blocker use in people with a normal QTc is individualized. Occasionally, beta blockade is not tolerated or breakthrough events occur despite adherence to beta blockade, and other interventions may be used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ICD</strong> – Implantable cardiac defibrillators (ICDs) are recommended in only selected patients with congenital LQTS; they are often overprescribed. An ICD is recommended for an individual with a history of sudden cardiac arrest. An ICD is appropriate for those with breakthrough arrhythmic syncope or seizures while adherent to beta blocker therapy, or as primary prevention in some high-risk asymptomatic individuals (eg, women with LQT2 and QTc &gt;500 ms or individuals with LQT2 or LQT3 [disease variants in <em>SCN5A</em>] and QTc &gt;550 ms). Among the largest LQTS specialty centers in the world, an ICD is used in less than one-fifth of patients. (See  <a class="medical medical_review" href="/d/html/921.html" rel="external">"Implantable cardioverter-defibrillators: Overview of indications, components, and functions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other specialized interventions</strong> – Additional interventions that may be appropriate for selected individuals include other medications (<a class="drug drug_general" data-topicid="9648" href="/d/drug information/9648.html" rel="external">mexiletine</a> or <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a>), left cardiac sympathetic denervation (LCSD) surgery, or intentional atrial pacing. However, this should be directed by a genetic cardiologist or a heart rhythm specialist with expertise in the risk stratification and treatment of patients with congenital LQTS.</p><p></p><p class="headingAnchor" id="H1820928797"><span class="h2">Individuals with a VUS or a negative genetic test result</span><span class="headingEndMark"> — </span>The implications of a variant of uncertain significance (VUS) or a negative test depend on the family history, personal history, and ECG findings:</p><p class="bulletIndent1"><span class="glyph">●</span>For an individual in a family with a known LQTS variant who has a reliable negative test for that variant  (<a class="graphic graphic_table graphicRef122437" href="/d/graphic/122437.html" rel="external">table 1</a>) and a normal ECG, the diagnosis of congenital LQTS is excluded. If there is a family history of documented or suspected congenital LQTS, genetic testing should initially be performed on the affected family members so that other family members can have directed testing for the familial variant if possible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For an individual with a clinical suspicion for congenital LQTS, including suggestive symptoms or ECG abnormalities without an alternative explanation (see <a class="local">'Overview of congenital LQTS'</a> above), negative or VUS results should be reviewed by a genetic cardiologist, pediatric/adult heart rhythm specialist, or cardiovascular genetic counselor to determine whether additional testing is needed. This may include re-evaluation of existing results, genetic testing for other variants or other LQTS genes, and/or clinical evaluation with ECG and possibly provocative testing. (See <a class="local">'Evaluations'</a> above.)</p><p></p><p class="bulletIndent1">As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the patient was predicted to have LQT1 by phenotype and the genetic test reports a VUS in the gene <em>KCNQ1</em>, then that VUS is almost certainly an LQT1-causative pathogenic variant.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the patient has clinically definite LQTS (phenotype positive) but a negative genetic test for all known LQTS-susceptibility genes, then there is either a missing acquired explanation for QT prolongation or a previously undiscovered genetic variant (genotype negative/phenotype positive LQTS). Such patients should be offered research-based evaluation for LQTS gene discovery [<a href="#rid3">3</a>].</p><p></p><p class="headingAnchor" id="H3959351489"><span class="h1">FIRST-DEGREE RELATIVES</span><span class="headingEndMark"> — </span>The following individuals should be evaluated with an electrocardiogram (ECG) at a minimum and with genetic testing in most cases: </p><p class="bulletIndent1"><span class="glyph">●</span>First-degree relatives of a person with a pathogenic or likely pathogenic variant in a congenital LQTS gene.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>First-degree relatives of a person with a VUS that is potentially concerning (based on clinical history, family history, or ECG findings).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>First-degree relatives of a person with negative genetic testing but a clinical history or ECG findings consistent with congenital LQTS.</p><p></p><p>If a congenital LQTS variant has been documented in a family, at-risk relatives can be tested exclusively for that variant  (<a class="graphic graphic_algorithm graphicRef129237" href="/d/graphic/129237.html" rel="external">algorithm 1</a>). However, if a disease variant has not been identified in the proband, or if a variant of uncertain significance (VUS) or a variant associated with another heart rhythm disorder has been identified, more extensive genetic testing of family members may be indicated. </p><p>Evaluation and management of relatives who test positive for LQTS disease variants or have an abnormal ECG without another cause are the same as described above. (See <a class="local">'Implications for management'</a> above.)</p><p class="headingAnchor" id="H1818692129"><span class="h1">RESOURCES</span></p><p>Drugs that prolong the QT interval are listed at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcrediblemeds.org%2F&amp;token=IqmMuUFQLkGgoX2gGpAMucirMSOQ1%2B5n1bp3d5NDcQWIuiYiyCp0aYIgzSi%2F5x8c&amp;TOPIC_ID=128462" target="_blank">https://crediblemeds.org/</a> (previously called QTdrugs.org). </p><p>Several UpToDate topics discuss congenital LQTS:</p><p class="bulletIndent1"><span class="glyph">●</span>Genetics – (See  <a class="medical medical_review" href="/d/html/1009.html" rel="external">"Congenital long QT syndrome: Pathophysiology and genetics"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms – (See  <a class="medical medical_review" href="/d/html/1036.html" rel="external">"Congenital long QT syndrome: Epidemiology and clinical manifestations"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis – (See  <a class="medical medical_review" href="/d/html/1053.html" rel="external">"Congenital long QT syndrome: Diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Management – (See  <a class="medical medical_review" href="/d/html/988.html" rel="external">"Congenital long QT syndrome: Treatment"</a>.)</p><p></p><p>Databases of genetics professionals are available:</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic counselors – National Society of Genetic Counselors (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F%3Freload%3Dtimezone&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflzQ%2BZ4POBsSFXQiuwJDn5pefBPIAES8nVSzeVi4Tr3mXQ%3D%3D&amp;TOPIC_ID=128462" target="_blank">NSGC</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical geneticists – American College of Medical Genetics and Genomics (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=128462" target="_blank">ACMG</a>)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</li><li><a class="nounderline abstract_t">Waddell-Smith KE, Skinner JR, Bos JM. Pre-Test Probability and Genes and Variants of Uncertain Significance in Familial Long QT Syndrome. Heart Lung Circ 2020; 29:512.</a></li><li><a class="nounderline abstract_t">Giudicessi JR, Wilde AAM, Ackerman MJ. The genetic architecture of long QT syndrome: A critical reappraisal. Trends Cardiovasc Med 2018; 28:453.</a></li><li><a class="nounderline abstract_t">Adler A, Novelli V, Amin AS, et al. An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome. Circulation 2020; 141:418.</a></li><li><a class="nounderline abstract_t">Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 2018; 138:e210.</a></li><li><a class="nounderline abstract_t">Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 2013; 10:1932.</a></li><li><a class="nounderline abstract_t">Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011; 8:1308.</a></li><li><a class="nounderline abstract_t">Schwartz PJ, Ackerman MJ. The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy. Eur Heart J 2013; 34:3109.</a></li><li><a class="nounderline abstract_t">Ackerman MJ. MY APPROACH to treatment of the congenital long QT syndromes. Trends Cardiovasc Med 2015; 25:67.</a></li><li class="breakAll">https://www.crediblemeds.org/ (Accessed on March 30, 2020).</li><li><a class="nounderline abstract_t">Chockalingam P, Crotti L, Girardengo G, et al. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol 2012; 60:2092.</a></li><li><a class="nounderline abstract_t">Ackerman MJ, Priori SG, Dubin AM, et al. Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent? Heart Rhythm 2017; 14:e41.</a></li></ol></div><div id="topicVersionRevision">Topic 128462 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32044265" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pre-Test Probability and Genes and Variants of Uncertain Significance in Familial Long QT Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29661707" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The genetic architecture of long QT syndrome: A critical reappraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31983240" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29084733" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24011539" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21787999" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23509228" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25442736" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : MY APPROACH to treatment of the congenital long QT syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25442736" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : MY APPROACH to treatment of the congenital long QT syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23083782" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27659101" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
